Journal articleEur J Cancer2018
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
- Journal
- Eur J Cancer
- Published
- 24 August 2018
- Citations
- 47
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 4
- Builds on itA Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma NCT01730222↗
- BackgroundShort-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL) NCT04793932↗
- BackgroundA Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Cl… NCT02670746↗
- BackgroundNab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (t… NCT01964430↗